×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
TBPH – theravance biopharma, inc. - ordinary shares (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
TBPH
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
2/3
08:03 am
tbph
Theravance Biopharma (NASDAQ:TBPH) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $40.00 price target on the stock.
Low
Report
Theravance Biopharma (NASDAQ:TBPH) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $40.00 price target on the stock.
1/24
05:10 am
tbph
Theravance Biopharma (NASDAQ:TBPH) had its "hold (c)" rating reaffirmed by analysts at Weiss Ratings.
Low
Report
Theravance Biopharma (NASDAQ:TBPH) had its "hold (c)" rating reaffirmed by analysts at Weiss Ratings.
12/12
09:35 am
tbph
Why The Narrative Around Theravance Biopharma Is Shifting After Trelegy Monetization And Strategic Review [Yahoo! Finance]
Low
Report
Why The Narrative Around Theravance Biopharma Is Shifting After Trelegy Monetization And Strategic Review [Yahoo! Finance]
12/5
07:03 pm
tbph
Why Theravance Biopharma (TBPH) is a Top Growth Stock for the Long-Term [Yahoo! Finance]
Medium
Report
Why Theravance Biopharma (TBPH) is a Top Growth Stock for the Long-Term [Yahoo! Finance]
12/3
07:02 am
tbph
Theravance Biopharma (NASDAQ:TBPH) is now covered by analysts at Oppenheimer Holdings, Inc.. They set an "outperform" rating on the stock.
Low
Report
Theravance Biopharma (NASDAQ:TBPH) is now covered by analysts at Oppenheimer Holdings, Inc.. They set an "outperform" rating on the stock.
Date
Time
Symbol
Company Name
Action
%Chg
11/10/2025
04:05 pm
TBPH
theravance biopharma, inc. - ordinary shares
BEAT
Report
22.7%
theravance biopharma, inc. - ordinary shares
8/12/2025
04:05 pm
TBPH
theravance biopharma, inc. - ordinary shares
BEAT
Report
4.2%
theravance biopharma, inc. - ordinary shares
5/8/2025
04:05 pm
TBPH
theravance biopharma, inc. - ordinary shares
MISS
Report
-9.3%
theravance biopharma, inc. - ordinary shares
2/26/2025
04:05 pm
TBPH
theravance biopharma, inc. - ordinary shares
MISS
Report
2.1%
theravance biopharma, inc. - ordinary shares
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
1/12
08:02 am
tbph
Form 8-K Theravance Biopharma, For: Jan 12
Medium
Report
Form 8-K Theravance Biopharma, For: Jan 12
12/8
06:30 am
tbph
Form 8-K Theravance Biopharma, For: Dec 08
Medium
Report
Form 8-K Theravance Biopharma, For: Dec 08
12/5
06:02 pm
tbph
Form 4 Theravance Biopharma, For: Dec 03 Filed by: Farnum Rhonda
Medium
Report
Form 4 Theravance Biopharma, For: Dec 03 Filed by: Farnum Rhonda
12/3
04:19 pm
tbph
Form 144 Theravance Biopharma, Filed by: Farnum Rhonda
Low
Report
Form 144 Theravance Biopharma, Filed by: Farnum Rhonda
12/1
07:03 pm
tbph
Form 4 Theravance Biopharma, For: Nov 26 Filed by: BROSHY ERAN
Medium
Report
Form 4 Theravance Biopharma, For: Nov 26 Filed by: BROSHY ERAN
11/26
04:02 pm
tbph
Form 144 Theravance Biopharma, Filed by: BROSHY ERAN
Low
Report
Form 144 Theravance Biopharma, Filed by: BROSHY ERAN
11/24
06:17 pm
tbph
Form 4 Theravance Biopharma, For: Nov 20 Filed by: Sawaf Aziz
Low
Report
Form 4 Theravance Biopharma, For: Nov 20 Filed by: Sawaf Aziz
11/24
06:15 pm
tbph
Form 4 Theravance Biopharma, For: Nov 20 Filed by: Miller Aine
Low
Report
Form 4 Theravance Biopharma, For: Nov 20 Filed by: Miller Aine
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
11/26
Theravance Biopharma to Present at Two Upcoming Investor Conferences
10.0%
4/9 Form 8-K Theravance Biopharma, For: Apr 09 5.1%
7/31 Q2/2019 6/30/2019 EPS -0.720 ZacksConsensus -1.220 ActVsEst 0.500 - Beat 4.8%
3/23 Stocks To Watch: Theravance Biopharma Sees Relative Strength Rating Jump To 94 [Investor's Business Daily] 4.7%
3/2 Theravance Biopharma Announces Closing of Private Placement of $400 Million Non-Recourse Notes 4.4%
4/20 Theravance Biopharma Announces Peer-Reviewed Publication Highlighting TD-1473 Program in the Journal of Crohn's and Colitis 4.1%
4/23 Theravance Biopharma Announces First Subject Dosed in Phase 1 Study of TD-0903, in Development for the Treatment of Hospitalized Patients with Acute Lung Injury Caused by COVID-19 3.9%
7/25 Theravance Biopharma to Report Second Quarter 2019 Financial Results on July 31 3.8%
11/6 Theravance Biopharma to Present at the 2019 Credit Suisse Healthcare Conference 3.6%
1/30 Theravance Biopharma Inc (NASDAQ: TBPH) was upgraded by analysts at BidaskClub from a "buy" rating to a "strong-buy" rating. 3.6%
4/9 Form 8-K Theravance Biopharma, For: Apr 09 5.1%
7/31 Q2/2019 6/30/2019 EPS -0.720 ZacksConsensus -1.220 ActVsEst 0.500 - Beat 4.8%
3/23 Stocks To Watch: Theravance Biopharma Sees Relative Strength Rating Jump To 94 [Investor's Business Daily] 4.7%
3/2 Theravance Biopharma Announces Closing of Private Placement of $400 Million Non-Recourse Notes 4.4%
4/20 Theravance Biopharma Announces Peer-Reviewed Publication Highlighting TD-1473 Program in the Journal of Crohn's and Colitis 4.1%
4/23 Theravance Biopharma Announces First Subject Dosed in Phase 1 Study of TD-0903, in Development for the Treatment of Hospitalized Patients with Acute Lung Injury Caused by COVID-19 3.9%
7/25 Theravance Biopharma to Report Second Quarter 2019 Financial Results on July 31 3.8%
11/6 Theravance Biopharma to Present at the 2019 Credit Suisse Healthcare Conference 3.6%
1/30 Theravance Biopharma Inc (NASDAQ: TBPH) was upgraded by analysts at BidaskClub from a "buy" rating to a "strong-buy" rating. 3.6%
TOP News Decliners
2/11
Theravance Biopharma Announces Pricing of Public Offering of Ordinary Shares
-11.5%
5/7 Theravance Biopharma, Inc. Reports First Quarter 2019 Financial Results and Provides Business Update -9.6%
4/30 Form 4 Theravance Biopharma, For: Apr 28 Filed by: YOUNG WILLIAM D -8.3%
9/25 Theravance Biopharma to Present at the 2019 Cantor Global Healthcare Conference -7.7%
2/10 Theravance Biopharma Announces Proposed Public Offering of Ordinary Shares -7.4%
3/24 Form DEF 14A Theravance Biopharma, For: Apr 28 -5.4%
4/29 Form 8-K Theravance Biopharma, For: Apr 28 -5.0%
5/22 Form 4 Theravance Biopharma, For: May 20 Filed by: WORBOYS PHILIP D -4.9%
6/14 Theravance Biopharma and Mylan Expand YUPELRI® (revefenacin) Development and Commercialization Agreement to Include China and Adjacent Territories -4.8%
5/18 Theravance Biopharma Inc (NASDAQ: TBPH) was downgraded by analysts at BidaskClub from a "sell" rating to a "strong sell" rating. -3.8%
5/7 Theravance Biopharma, Inc. Reports First Quarter 2019 Financial Results and Provides Business Update -9.6%
4/30 Form 4 Theravance Biopharma, For: Apr 28 Filed by: YOUNG WILLIAM D -8.3%
9/25 Theravance Biopharma to Present at the 2019 Cantor Global Healthcare Conference -7.7%
2/10 Theravance Biopharma Announces Proposed Public Offering of Ordinary Shares -7.4%
3/24 Form DEF 14A Theravance Biopharma, For: Apr 28 -5.4%
4/29 Form 8-K Theravance Biopharma, For: Apr 28 -5.0%
5/22 Form 4 Theravance Biopharma, For: May 20 Filed by: WORBOYS PHILIP D -4.9%
6/14 Theravance Biopharma and Mylan Expand YUPELRI® (revefenacin) Development and Commercialization Agreement to Include China and Adjacent Territories -4.8%
5/18 Theravance Biopharma Inc (NASDAQ: TBPH) was downgraded by analysts at BidaskClub from a "sell" rating to a "strong sell" rating. -3.8%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: